Table 4. Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.
| Height SDS | Change in height SDS per year | |||
|---|---|---|---|---|
| ß ± SE | p | ß ± SE | p | |
| Age (y) | 0.06 ± 0.02 | 0.0004 | 0.009 ± 0.001 | 0.09 |
| Sex (male) | -0.52 ± 0.14 | 0.0002 | ||
| Height SDS | - | -0.03 ± 0.013 | 0.01 | |
| Midparental height (cm) | 0.06 ± 0.008 | <.0001 | ||
| BMI SDS | -0.09 ± 0.04 | 0.037 | ||
| Physical activity level (0–4) | 0.05 ± 0.01 | 0.001 | ||
| rhGH therapy | 0.15 ± 0.07 | 0.04 | ||
| BAP SDS | 0.03 ± 0.01 | 0.002 | ||
| TRAP SDS | 0.03 ± 0.01 | 0.04 | ||
| Sclerostin SDS | 0.13 ± 0.05 | 0.005 | ||
| cFGF-23 SDS | 0.04 ± 0.01 | 0.001 | ||
| eGFR (ml/min/1.73m2) | 0.03 ± 0.007 | <.0001 | 0.002 ±0.002 | 0.21 |
| Serum bicarbonate (mM) | 0.04 ± 0.015 | 0.01 | ||
| Serum Pi (mM) | 0.14 ± 0.05 | 0.005 | ||
| Serum 25OHD (μg/l, log) | 0.006 ± 0.004 | 0.2 | 0.05 ± 0.02 | 0.04 |
| Serum CRP (mg/L, log) | -0.07 ± 0.04 | 0.07 | ||
| Model R2 | 0.24 | 0.10 | ||
The prospective change in height SDS during one year of observation was positively associated with higher BAP and TRAP5b SDS, lower baseline height SDS and rhGH therapy.
Interestingly, physical activity showed a positive association to prospective growth.
A case-control study was performed to obtain an unbiased analysis of the impact of rhGH on the bone marker pattern. For 41 rhGH treated patients an equal number of untreated control subjects matched by age, sex, country of residence, CKD duration, eGFR and serum phosphorus, iPTH and CRP was identified (see Table 5).